Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

Avacta Group PLC (AVCT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
47.40 +6.90    +17.04%
25/07 - Closed. Currency in GBP
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BYYW9G87 
SEDOL:  BYYW9G8
  • Volume: 12,283,369
  • Bid/Ask: 45.00 / 50.00
  • Day's Range: 40.55 - 48.00
Avacta Group 47.40 +6.90 +17.04%

Avacta Group PLC Company Profile

 
Get an in-depth profile of Avacta Group PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

151

Equity Type

ORD

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.

Contact Information

Address Scale Space White City Imperial College Campus 58 Wood Lane
London, W12 7RZ
United Kingdom
Phone 44 203 9110353
Fax -

Top Executives

Name Age Since Title
Paul Andrew Fry 59 2020 Independent Non-Executive Director
Alan Ho - 2024 Member of Scientific Advisory Board
William D. Tap - 2024 Chairman of Scientific Advisory Board
Christina Marie Coughlin 55 2022 CEO & Executive Director
Anthony F. Yu - 2024 Member of Scientific Advisory Board
Lee D. Cranmer - 2024 Member of Scientific Advisory Board
Shaun Edward Chilton 58 2023 Independent Non-Executive Chairman
Andrea Napolitano - 2024 Member of Scientific Advisory Board
Mark Alan Goldberg 71 2021 Independent Non-Executive Director
Robin Jones - 2024 Member of Scientific Advisory Board
David John Bryant 58 2025 Independent Non-Executive Director
Richard Ian Hughes 57 2025 Independent Non-Executive Director
Robert Metcalf - 2024 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AVCT Comments

Write your thoughts about Avacta Group PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email